{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=44", "query": { "condition": "Pancreatic Carcinoma", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 2231, "total_pages": 224, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Carcinoma&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T03:47:59.831Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05669482", "title": "Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS Activating Mutation", "Metastatic Cancer", "Pancreas Cancer", "Neoplasms Pancreatic", "Malignant Neoplasm of Pancreas" ], "interventions": [ { "name": "avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-03-22", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 12, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05669482" }, { "nct_id": "NCT01803282", "title": "Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Non-small Cell Lung Cancer", "Esophagogastric Cancer", "Colorectal Cancer", "Breast Cancer" ], "interventions": [ { "name": "Andecaliximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 236, "start_date": "2013-03-29", "completion_date": "2019-04-23", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01803282" }, { "nct_id": "NCT01465659", "title": "Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Alpha Cell Carcinoma", "Pancreatic Beta Islet Cell Carcinoma", "Pancreatic Delta Cell Carcinoma", "Pancreatic G-cell Carcinoma", "Recurrent Islet Cell Carcinoma" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "pazopanib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2011-12-12", "completion_date": "2021-01-27", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 5, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01465659" }, { "nct_id": "NCT06079346", "title": "A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "OT-101", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotelic Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 455, "start_date": "2024-05-01", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 2, "location_summary": "Detroit, Michigan • Houston, Texas", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06079346" }, { "nct_id": "NCT02333188", "title": "Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of Unknown Primary", "Adult Cholangiocarcinoma", "Gallbladder Carcinoma", "Gastric Adenocarcinoma", "Malignant Gastrointestinal Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Stage III Ampulla of Vater Cancer", "Stage III Pancreatic Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Gastric Cancer", "Stage IV Ampulla of Vater Cancer", "Stage IV Gallbladder Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-12", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 8, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02333188" }, { "nct_id": "NCT01501903", "title": "Standard Versus Fanning Techniques for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Tumors" ], "interventions": [ { "name": "Standard", "type": "PROCEDURE" }, { "name": "Fanning", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Shyam Varadarajulu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "19 Years to 90 Years" }, "enrollment_count": 52, "start_date": "2011-09", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2012-02-02", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01501903" }, { "nct_id": "NCT04940286", "title": "Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Resectable Pancreatic Adenocarcinoma", "Resectable Pancreatic Adenocarcinoma", "Stage IA Pancreatic Cancer AJCC v8", "Stage IB Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oleclumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-09-28", "completion_date": "2027-10-30", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940286" }, { "nct_id": "NCT04900818", "title": "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Gastric Cancer", "Gastroesophageal Junction Carcinoma", "Esophageal Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "TJ033721 (givastomig)", "type": "DRUG" }, { "name": "TJ033721 (givastomig) , nivolumab, chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), chemotherapy", "type": "DRUG" }, { "name": "TJ033721 (givastomig), durvalumab, chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2021-06-29", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 11, "location_summary": "Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Layfayette", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900818" }, { "nct_id": "NCT04581343", "title": "A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pancreatic Cancer Action Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-11-02", "completion_date": "2023-02-27", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04581343" }, { "nct_id": "NCT01166490", "title": "A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Neoplasms", "Pancreatic Neoplasms" ], "interventions": [ { "name": "ASG-5ME", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2010-07", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-08-27", "last_synced_at": "2026-10-20T03:47:59.831Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01166490" } ] }